Skip to main content
Erschienen in: Clinical Journal of Gastroenterology 4/2017

24.05.2017 | Case Report

Negative conversion of high serum p53 antibody titers in a patient with gastric cancer at 31 months after surgery

verfasst von: Kenji Murayama, Tatsuki Nanami, Takashi Suzuki, Yoko Oshima, Satoshi Yajima, Tetsuo Nemoto, Hideaki Shimada

Erschienen in: Clinical Journal of Gastroenterology | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

We performed distal gastrectomy with D2 lymph node dissection, pathological stage was Stage IB (T2N0M0), in a 68-year-old male with gastric adenocarcinoma. We then monitored serum p53 antibody titers for 5 years and found it consistently decreased, without disease recurrence. Although the s-p53-Ab titer remained positive even after 2 years, it decreased to 16.5, 4.45, 2.66, 1.55, and 1.18 U/ml at 3 months, 7 months, 1 year, 2 years and 3 years after surgery, respectively. The s-p53-Ab titer finally converted from positive to negative at 31 months postoperatively without any sign of recurrence by computed tomography examination at 5 years after surgery. This case report shows that the changing pattern of s-p53-Ab titer after surgery may be useful to identify patients without recurrence. Further studies are required to gain a more precise understanding of the clinical impact of s-p53-Ab titer monitoring in gastric adenocarcinoma.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Shiota G, Ishida M, Noguchi N, et al. Clinical significance of serum p53 antibody in patients with gastric cancer. Res Commun Mol Pathol Pharmacol. 1998;99:41–51.PubMed Shiota G, Ishida M, Noguchi N, et al. Clinical significance of serum p53 antibody in patients with gastric cancer. Res Commun Mol Pathol Pharmacol. 1998;99:41–51.PubMed
2.
Zurück zum Zitat Shimizu K, Ueda Y, Yamagishi H. Titration of serum p53 antibodies in patients with gastric cancer: a single-institute study of 40 patients. Gastric Cancer. 2005;8:214–9.CrossRefPubMed Shimizu K, Ueda Y, Yamagishi H. Titration of serum p53 antibodies in patients with gastric cancer: a single-institute study of 40 patients. Gastric Cancer. 2005;8:214–9.CrossRefPubMed
3.
Zurück zum Zitat Nakajima K, Suzuki T, Shimada H, et al. Detection of preoperative serum anti-p53 antibodies in gastric cancer. Tumour Biol. 1999;20:147–52.CrossRefPubMed Nakajima K, Suzuki T, Shimada H, et al. Detection of preoperative serum anti-p53 antibodies in gastric cancer. Tumour Biol. 1999;20:147–52.CrossRefPubMed
4.
Zurück zum Zitat Shimada H, Shiratori T, Takeda A, et al. Perioperative changes of serum p53 antibody titer is a predictor for survival in patients with esophageal squamous cell carcinoma. World J Surg. 2009;33:272–7.CrossRefPubMed Shimada H, Shiratori T, Takeda A, et al. Perioperative changes of serum p53 antibody titer is a predictor for survival in patients with esophageal squamous cell carcinoma. World J Surg. 2009;33:272–7.CrossRefPubMed
5.
Zurück zum Zitat Shimada H, Nagata M, Cho A, et al. Long-term monitoring of serum p53 antibody after neoadjuvant chemotherapy and surgery for esophageal adenocarcinoma: report of a case. Surg Today. 2014;44:1957–61.CrossRefPubMed Shimada H, Nagata M, Cho A, et al. Long-term monitoring of serum p53 antibody after neoadjuvant chemotherapy and surgery for esophageal adenocarcinoma: report of a case. Surg Today. 2014;44:1957–61.CrossRefPubMed
6.
Zurück zum Zitat Maehara Y, Kakeji Y, Watanabe A, et al. Clinical implications of serum anti-p53 antibodies for patients with gastric carcinoma. Cancer. 1999;85:302–8.CrossRefPubMed Maehara Y, Kakeji Y, Watanabe A, et al. Clinical implications of serum anti-p53 antibodies for patients with gastric carcinoma. Cancer. 1999;85:302–8.CrossRefPubMed
7.
Zurück zum Zitat Werner S, Chen H, Tao S, et al. Systematic review: serum autoantibodies in the early detection of gastric cancer. Int J Cancer. 2015;136:2243–52.CrossRefPubMed Werner S, Chen H, Tao S, et al. Systematic review: serum autoantibodies in the early detection of gastric cancer. Int J Cancer. 2015;136:2243–52.CrossRefPubMed
8.
Zurück zum Zitat Tokunaga R, Sakamoto Y, Nakagawa S, et al. The utility of tumor marker combination, including serum p53 antibody, in colorectal cancer treatment. Surg Today. 2017;47:636–42.CrossRefPubMed Tokunaga R, Sakamoto Y, Nakagawa S, et al. The utility of tumor marker combination, including serum p53 antibody, in colorectal cancer treatment. Surg Today. 2017;47:636–42.CrossRefPubMed
9.
Zurück zum Zitat Suzuki T, Shimada H, Ushigome M, et al. Three-year monitoring of serum p53 antibody during chemotherapy and surgery for stage IV rectal cancer. Clin J Gastroenterol. 2016;9:55–8.CrossRefPubMed Suzuki T, Shimada H, Ushigome M, et al. Three-year monitoring of serum p53 antibody during chemotherapy and surgery for stage IV rectal cancer. Clin J Gastroenterol. 2016;9:55–8.CrossRefPubMed
10.
Zurück zum Zitat Shimada H, Ochiai T, Nomura F. Japan p53 Antibody Research Group. Titration of serum p53 antibodies in 1,085 patients with various types of malignant tumors: a multiinstitutional analysis by the Japan p53 Antibody Research Group. Cancer. 2003;97:682–9.CrossRefPubMed Shimada H, Ochiai T, Nomura F. Japan p53 Antibody Research Group. Titration of serum p53 antibodies in 1,085 patients with various types of malignant tumors: a multiinstitutional analysis by the Japan p53 Antibody Research Group. Cancer. 2003;97:682–9.CrossRefPubMed
11.
Zurück zum Zitat Japanese Gastric Cancer Association: Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14:101–12.CrossRef Japanese Gastric Cancer Association: Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14:101–12.CrossRef
12.
Zurück zum Zitat Shimada H, Noie T, Ohashi M, et al. Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association. Gastric Cancer. 2014;17:26–33.CrossRefPubMed Shimada H, Noie T, Ohashi M, et al. Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association. Gastric Cancer. 2014;17:26–33.CrossRefPubMed
13.
Zurück zum Zitat Shimada H, Nabeya Y, Okazumi S, et al. Prognostic significance of serum p53 antibody in patients with esophageal squamous cell carcinoma. Surgery. 2002;132:41–7.CrossRefPubMed Shimada H, Nabeya Y, Okazumi S, et al. Prognostic significance of serum p53 antibody in patients with esophageal squamous cell carcinoma. Surgery. 2002;132:41–7.CrossRefPubMed
Metadaten
Titel
Negative conversion of high serum p53 antibody titers in a patient with gastric cancer at 31 months after surgery
verfasst von
Kenji Murayama
Tatsuki Nanami
Takashi Suzuki
Yoko Oshima
Satoshi Yajima
Tetsuo Nemoto
Hideaki Shimada
Publikationsdatum
24.05.2017
Verlag
Springer Japan
Erschienen in
Clinical Journal of Gastroenterology / Ausgabe 4/2017
Print ISSN: 1865-7257
Elektronische ISSN: 1865-7265
DOI
https://doi.org/10.1007/s12328-017-0749-9

Weitere Artikel der Ausgabe 4/2017

Clinical Journal of Gastroenterology 4/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.